Skip to main content
      Do biologics prevent PsA?

      Retro cohort analysis EHR through natural language processing

      5 years trends
      PsO treated w/

      Aurelie Najm AurelieRheumo

      6 days 20 hours ago
      Do biologics prevent PsA? Retro cohort analysis EHR through natural language processing 5 years trends PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies Adjustment on several confounding Prospective data heavily https://t.co/W9MFaWNbWC
      ACR25 coming to a close with Clinical Year in Preview

      For PsA, can biologics prevent damage? If so, which one?

      Diffic

      Jiha Lee JihaRheum

      6 days 20 hours ago
      ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34
      #YearInPreview at #ACR25

      @DrLauraCoates introduces the session with a teaser for work that will be presented later toda

      Mrinalini Dey DrMiniDey

      6 days 20 hours ago
      #YearInPreview at #ACR25 @DrLauraCoates introduces the session with a teaser for work that will be presented later today. Are we entering an era in which we will be able to prevent #PsA? Find out more at 12:00 today, Abs #2689 @RheumNow https://t.co/GDTBGNTCCd
      From Pain to Wellness in PsA
      Hydroxychloroquine Blood Levels
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      6 days 21 hours ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      Rheum Now Rheumatology Round-Up — LIVE
      Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheu

      Dr. John Cush RheumNow

      6 days 22 hours ago
      Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25. 📡 Live https://t.co/GXxmtoluBc
      The DIPSA study: can diet improve PsA?

      Finally a RCT, and the general message is Loose weight, regardless of the diet!

      Aurelie Najm AurelieRheumo

      6 days 22 hours ago
      The DIPSA study: can diet improve PsA? Finally a RCT, and the general message is Loose weight, regardless of the diet! 3 arms: -Mediterranean diet 31pts -Low-calorie Dietary Approaches (DASH-LC) 30pts -Standard of care 31pts Primary outcome change in DAPSA wk 12 DASH-LC https://t.co/XH9Xdn0g96
      In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under a

      Antoni Chan MD (Prof) synovialjoints

      6 days 22 hours ago
      In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf
      Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chan

      Richard Conway RichardPAConway

      6 days 22 hours ago
      Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7
      Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria

      ♥️Criteria score >/= 11pts
      🔸SN 77.8

      sheila RHEUMarampa

      6 days 22 hours ago
      Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria ♥️Criteria score >/= 11pts 🔸SN 77.8%; SP 95.9% 🔸OR 82.6 Huge endeavor towards standardization of SHI to help improve patient outcomes in the future 👏👏 #ACR25 @RheumNow https://t.co/QrgYlksjZB
      Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo.

      ΔESSDAI at 48wk:

      Jiha Lee JihaRheum

      6 days 22 hours ago
      Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo. ΔESSDAI at 48wk: Ianalumab QM > PBO, statistically significant But ΔESSDAI ≈ 0.5–1 pt (vs PBO) below MCII (≥ 3) Promising biology, modest clinical gain #ACR25 @RheumNow LB24 https://t.co/8y580ch9iJ
      ×